Literature DB >> 12498999

Serum nitrates and vasoactive intestinal peptide in patients with gastroesophageal reflux disease.

Samar K Kassim1, Maha El Touny, Magdy El Guinaidy, Mohamed Abd El Moghni, Anwar Abd El Mohsen.   

Abstract

BACKGROUND: The normal esophageal motility is a balance between excitatory cholinergic "muscarinic" innervations and noncholinergic nonadrenergic inhibitory innervations. The latter is mediated by nitric oxide (NO) and/or vasoactive intestinal polypeptide (VIP).
METHODS: The study included 50 patients with gastro-esophageal reflux disease (GERD), and 10 healthy controls of matched age and sex. Patients were divided into five groups according to the degree of lower end esophagitis (Savary-Miller classification). Serum VIP was measured using enzyme immunoassay after peptide purification. Serum nitrate as an index of nitric oxide generation was determined biochemically.
RESULTS: Serum nitrate and VIP levels were significantly higher in GERD patients than the control group (p < 0.001). Grade 0 serum nitrates was significantly higher than the control group (p < 0.05) with some overlap between the individual values of the two groups. Serum VIP was significantly higher in grade 0 group compared to control group (p < 0.001) with no overlap in the individual values. There was a significant positive correlation between the grade of lower end esophagitis and each of serum nitrate and VIP (p < 0.001), as well as between serum nitrate and each of serum VIP, cigarette smoking index (CSI) and BMI (p < 0.001).
CONCLUSION: Abnormally high levels of serum VIP and NO may have a role in the pathogenesis of GERD. Exposure of esophageal mucosa to noxious effect of acid refluxed due to the relaxant effect of VIP on lower esophageal sphincter may cause increased NO levels. BMI and CSI are risk factors for GERD progression. Copyright 2002 The Canadian Society of Clinical Chemists

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12498999     DOI: 10.1016/s0009-9120(02)00399-5

Source DB:  PubMed          Journal:  Clin Biochem        ISSN: 0009-9120            Impact factor:   3.281


  6 in total

1.  Do elevated plasma vasoactive intestinal polypeptide (VIP) levels cause small intestinal motor disturbances in humans?

Authors:  Jutta Keller; Jan C Mueller-Wolf; Keihan Ahmadi-Simab; Christiane Fibbe; Ulrich Rosien; Peter Layer
Journal:  Dig Dis Sci       Date:  2005-02       Impact factor: 3.199

Review 2.  Neuroendocrine cells derived chemokine vasoactive intestinal polypeptide (VIP) in allergic diseases.

Authors:  Alok K Verma; Murli Manohar; Sathisha Upparahalli Venkateshaiah; Anil Mishra
Journal:  Cytokine Growth Factor Rev       Date:  2017-09-23       Impact factor: 7.638

3.  Associations between the severity of reflux esophagitis in children and changes in oxidative stress, serum inflammation, vasoactive intestinal peptide and motilin.

Authors:  Yingqin Deng; Li Pan; Wenjie Qian
Journal:  Exp Ther Med       Date:  2019-09-06       Impact factor: 2.447

4.  Gastroesophageal reflux disease and paraneoplastic neurological syndrome associated with long-term survival in limited stage small-cell lung cancer.

Authors:  Vinicius Ernani; Lin Du; Helen J Ross; Joanne E Yi; Jason A Wampfler; Steven E Schild; Hao Xie; Karen L Swanson; Henry D Tazelaar; Ping Yang
Journal:  Thorac Cancer       Date:  2022-02-23       Impact factor: 3.500

5.  Inverse association between gastroesophageal reflux and blood pressure: results of a large community based study.

Authors:  Liam J Murray; Peter McCarron; Roger B McCorry; Lesley A Anderson; Athene J Lane; Brian T Johnston; George Davey Smith; Richard F Harvey
Journal:  BMC Gastroenterol       Date:  2008-04-15       Impact factor: 3.067

6.  Alterations of Mast Cells in the Esophageal Mucosa of the Patients With Non-Erosive Reflux Disease.

Authors:  Yue Yu; Xiping Ding; Qiaomin Wang; Li Xie; Wen Hu; Ke Chen
Journal:  Gastroenterology Res       Date:  2011-03-20
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.